Kornimate/medical-research-clean huggingface dataset:
neoadjuvant adebrelimab and chemotherapy in high-rish er+/her2- bc

Conditions: Breast Cancer

Summary: investigators plan to conduct a single-arm clinical study of adebelimab, a novel pd-l1 inhibitor, in the neoadjuvant treatment of early or locally advanced high-risk er+/her2- breast cancer, to explore whether the addition of immune checkpoint inhibitors to traditional neoadjuvant chemotherapy can improve the pathologic complete response rate (pcr) of patients, evaluate its therapeutic safety, and further analyze the biomarkers of the efficacy of neoadjuvant immunotherapy for er+/her2- breast cancer, so as to support the clinical application of the drug.


Eligibility criteria:
inclusion criteria: * pathologically diagnosed as unilateral primary invasive breast cancer with a) ct1c-t2n1-3 or ct3-4n0-3, b) tumor grade 3 or grade 2 with pr- or ki67 \&gt; 20%; * ihc er expression ≥1%; ihc her2 0 or 1+; ihc her2 2+ and no amplification in fish test; * at least one measurable lesion according to recist 1.1; * available core needle biopsy samples for pd-l1 status testing; * ecog 0 or 1 within 10 days prior to initiation of treatment; * not currently pregnant or breastfeeding, agree to strict contraception during treatment and at least 6 months after last dose; * intact hematologic, liver, renal and heart functions; * signed written informed consent. exclusion criteria: * bilateral invasive breast cancer or stage iv breast cancer; * severe heart disease; * diagnosed as immune deficiency or receiving systemic steroid therapy or any form of immuno-suppressive therapy within 7 days prior to the first dose of treatment; * had active autoimmune diseases requiring systemic therapy within the past 2 years; * severe systemic infections or other serious medical conditions; * other malignant tumors in the past 5 years, except for cured carcinoma in situ of the cervix and skin cancer without melanoma; * history of hiv infection; * active hbv or hcv infection; * known allergies or intolerance to the therapeutic drug or its excipients; * history of application of any immunotherapy targeting pd-1/pd-l1/t cell receptors; * judged by the investigator to be unsuitable to participate in this study.

Keywords: breast cancer er+/her2- neoadjuvant adebrelimab
the effect of intraoperative magnesium sulfate infusion on the postoperative recovery

Conditions: Postoperative Pain

Summary: evaluating analgesic effect of intraoperative magnesium sulfate infusion in the outpatient surgery case


Eligibility criteria:
inclusion criteria: * aged between 18-65 year-old-patient (asa i-ii) who are planned to undergoing day surgery exclusion criteria: * asa class ≥ iii * suspected imbalance of electrolyte * myocardial damage or conduction delay * myasthenia gravis or other neuromuscular disease * impaired renal function * already using any type of analgesia * denial of participating in the study or not giving the informed consent
a dietary intervention- randomized controlled trial (direct) study; bgu-harvard-robarts collaboration

Conditions: Obesity; CHD

Summary: aim-to conduct a randomized clinical intervention study to compare three diets (low-fat, low-carbohydrate and mediterranean diet) for weight loss

aim-to conduct a randomized clinical intervention study to compare three diets (low-fat, low-carbohydrate and mediterranean diet) for weight loss

Eligibility criteria:
inclusion criteria: * bmi\>27 * age\>40 * history of chd or diabetes in any age or bmi level exclusion criteria: * pregnant or lactating women. * active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. * serum creatinine \> 3 mg/dl. * liver dysfunction ( ³ 2 fold level of alt and ast enzymes). * participation in another trial in which active intervention is being received. * any intestinal problem that would prevent the patient from eating one of the test diets (for example, gastric stapling that might prevent consumption of vegetables).
evaluation of antimicrobial efficacy and postoperative pain after using silver nanoparticles and chitosan nanoparticles against enterococcus faecalis and candida albicans biofilm

Conditions: Endodontic Disease

Summary: silver nanoparticles possess unique physicochemical and biological properties in addition to their antibacterial capabilities. similarly, zinc oxide nanoparticles have demonstrated antibacterial effects against a wide range of bacteria, including heat and pressure resistant spores. given these characteristics, it would be valuable to evaluate and compare a new irrigation solution containing nanosilver and nanozinc-oxide particles with sodium hypochlorite. furthermore, chitosan nanoparticles are expected to exhibit enhanced antibacterial activity compared to regular-sized chitosan due to their ability to penetrate and disrupt microbial cell membranes. consequently, the current study aims to assess and compare the antibacterial activity of silver nanoparticles and chitosan nanoparticles, as well as their impact on post-operative pain.


Eligibility criteria:
inclusion criteria: * medically stable healthy patients (category: american society of anesthesiologists class i). * the patient ranges in age from 20 to 40. * no sexual orientation * necrotic pulp evaluated by thermal or electrical pulp testing. * enough crown structure to provide adequate isolation. * one root and one canal. * patients' desire to engage in this research. * patients' comprehension of the visual analogue scale (vas). * patients' ability to sign informed consent. exclusion criteria: * endodontic treatment for the tooth previously. * teeth with poor conditions for using rubber dams. * vital pulp tissue was observed throughout the treatment. * patients who have a medical condition. * teeth with open apices that are immature * women who are pregnant or breastfeeding. * psychologically disturbed patients. * patients having a history of allergy to any of the research drugs were barred from participation. * a periodontally affected tooth with grade 2 or 3 mobility.
dissemination of the donor application: utilizing social media to identify potential live organ donors

Conditions: End Stage Renal Disease; End Stage Liver Disease

Summary: this study utilizes a web-based application to help patients on the organ transplant waitlist communicate patient's need for a living donor via social media and provide interested potential donors the opportunity to engage with the evaluation process.

barriers to identifying a live donor include lack of education and hesitance to initiate a conversation about live donation. for these reasons, many transplant candidates are hesitant to discuss candidate's illness and are therefore reluctant to pursue live donor transplantation. the investigators hypothesize that utilization of social media to spread awareness about candidate's illness and candidate's need for a live donor will enable many transplant candidates to successfully identify live donors. in this study, participants will use a novel web-based application, called the "donor app", to create and share candidate's story via facebook and other social networks to assist in the search for a live donor.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * on the kidney-only or liver-only transplant waiting list at a collaborating center exclusion criteria: * younger than 18 years of age * not on the kidney or liver transplant waiting list * on multiple organ transplant waiting lists

Keywords: live donor transplant social media advocacy education living donation the donor app
autonomic effects of t4 mobilization in asymptomatic subjects

Conditions: Other Disorders of the Autonomic Nervous System; Vertebra; Degeneration

Summary: the purpose of this study is to determine whether passive accessory intervertebral mobilization applied to the fourth thoracic vertebra produces autonomic effects.

asymptomatic subjects will be recruited to this study. pressure pain threshold, heart rate, heart rate variability and skin conductance will be measured before, immediately after and fifteen minutes after the intervention. subjects will be randomized into three groups: passive accessory intervertebral mobilization one, passive accessory intervertebral mobilization two and placebo group. the researcher that will do the intervention will be blinded to the outcomes measures, and the researcher that will do the measurements will be blind to the intervention.

Eligibility criteria:
inclusion criteria: * asymptomatic subjects * aged between 18 - 40 years old * portuguese readers and writers exclusion criteria: * history of lesion or surgery to the spine

Keywords: autonomic effects spinal mobilization clinical trial
effect of liraglutide on glucose profiles and gastric emptying in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. the aim of this trial is to determine the effect of nnc 90-1170 (liraglutide) on glucose and hormonal profiles, fasting gluconeogenesis and insulin secretion in subjects with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * diet treated and/or subjects in monotherapy with max. 50 % of maximal dose of sulphonylurea (su). in addition, subjects in treatment with metformin and/or repaglinide could be included * body mass index (bmi) maximum 35 kg/m\^2 * fasting plasma glucose 7-15 mmol/l, both inclusive exclusion criteria: * impaired liver function * impaired renal function * anaemia * cardiac disease * uncontrolled treated/untreated hypertension * recurrent major hypoglycaemia as judged by the investigator * known or suspected allergy to trial product or related products * females of child bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures * current treatment with thiazolidinediones or chronic daily use of insulin (more than 7 days) within three months in the absence of intercurrent illness * loss of more than 400 ml blood during the three months prior to study start * allergy to paracetamol
validate valsartan and supportive measures - impact on drug adherence of treated hypertensive patients

Conditions: Hypertension

Summary: the purpose of this study is to assess the impact of supportive measures on the drug adherence of patients with essential hypertension


Eligibility criteria:
inclusion criteria: * male or female patients \>= 18 years * females must be either post-menopausal for one year, surgically sterile or using effective contraceptive methods (e.g. barrier method with spermicide, intra-uterine device, hormonal contraceptives). * patients with mild essential hypertension: systolic blood pressure ≥ 140 mmhg and \< 170 and/or diastolic blood pressure ≥ 90 mmhg and \< 105 mmhg" exclusion criteria: * moderate and severe hypertension * pregnant or nursing women * a history of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, stroke, and heart failure nyha ii - iv other protocol-defined inclusion/exclusion criteria may apply

Keywords: hypertension, valsartan, compliance
evaluation of the prevention of thromboembolic disease in patients with a lower limb trauma, non surgical, in winter sports resort

Conditions: Leg Injuries; Winter Sport Resorts; Outpatients

Summary: the purpose of this study is to evaluate the impact of thromboembolic diseases and heparin complications in patients with a lower limb trauma supported by physicians of mountain.

the "m2m-thrombose" study is a prospective epidemiological multicenter study involving patients with a lower limb trauma in winter sport resorts. the following initial data required are type of immobilization, treatment with lmwh (low molecular weight heparin), type of injury (serious or not) and the rolling of the step (normal or abnormal) or no weight bearing. a 3 month follow-up by phone will be realized by the investigation clinical center in grenoble. data about risk factors of thromboembolic diseases, anticoagulant therapy, medical history, new event since inclusion (hospitalization, surgery, lower limb trauma or thromboembolic events) will be collected.

Eligibility criteria:
inclusion criteria: * patients seen during a consultation with a physician of mountain * lower limb trauma seen within 48 hours * patient resident in france exclusion criteria: * conditions requiring an immediate hospitalization * prisoners * pregnant, nursing or parturient woman * refused participation in follow-up

Keywords: lmwh heparin immobilization anticoagulant prophylaxis leg injuries thromboembolism
the impact of conventional hemodialysis and renal transplantation on the global longitudinal strain of the left ventricle

Conditions: Cardiovascular Diseases; Chronic Kidney Diseases; Fibrosis

Summary: the objective of this study is to evaluate a group of patients with chronic kidney disease in stages 3-5 by conventional 2d echocardiography, tissue doppler techniques and speckle tracking - lv gls and determine the correlation of ultrasound parameters with mortality. additionally, fibrosis-related biomarkers will be studied in this population.


Eligibility criteria:
inclusion criteria: * egfr \< 15 ml/min/1.73m2 (ckd - epi) * nyha class i-ii * hemodynamic stability exclusion criteria: * age \< 18 years old * poor acoustic window * atrial fibrillation * recent acute myocardial infarction * pacemaker
licorice versus sugar-water gargling for pain in patients recovering from ear-nose-throat and maxilla-facial surgery

Conditions: Pain, Postoperative; Surgery, Oral

Summary: our primary aim is to determine whether licorice gargling provides meaningful analgesia after oral surgery. specifically, we propose to test the primary hypothesis that gargling with licorice solution reduces pain after oral surgery more than gargling with sugar water. because effective analgesia can reduce pain and/or opioid consumption, we will jointly evaluate verbal response pain scores and overall morphine consumption considering licorice to be beneficial only if it proves non-inferior on both measures and superior on at least one.


Eligibility criteria:
inclusion criteria: 1. oropharyngeal surgeries including:panendoscopic surgery; elective tonsillectomy/adenotonsillectomy; demarcation and biopsy of suspected tongue carcinoma 2. anticipated extubation in the operating room 3. american society of anesthesia physical status 1-3 exclusion criteria: 1. rapid sequence induction 2. known or suspected allergy to licorice or its ingredients 3. liver failure with bleeding disorders 4. insulin-dependent diabetes mellitus 5. use of non-steroidal anti-inflammatory drug medication within 24 hours before surgery 6. chronic opioid use 7. dementia or inability to use an iv patient-controlled-analgesia (pca) pump 8. superinfected oropharyngeal tumors 9. planned postoperative mechanical ventilation or admission to intensive care unit (icu)

Keywords: postoperative pain anesthesia oral surgery
female urine, vaginal & endocervical swab & cervical specimen collections for aptima trichomonas vaginalis assay testing

Conditions: Trichomonas Vaginalis

Summary: the objective of this study is to obtain female first-catch urine, vaginal swab, endocervical swab, and cervical specimens collected in preservcyt solution ("preservcyt specimens") for testing with the aptima trichomonas vaginalis (atv) assay. these specimens will be used to demonstrate assay performance on the panther system is comparable to performance on the tigris system.


Eligibility criteria:
inclusion criteria: * subject must be female and attend a participating clinic * subject must be at least 14 years of age at the time of enrollment and is currently sexually active (has had vaginal intercourse within the past 12 months) * the subject and/or legally authorized representative is willing to undergo the informed consent process prior to study participation (a minor will need the documented consent of her parent or legal guardian, unless the site has an institutional review board (irb)- approved waiver for parental consent for minors) * in addition, the subject must meet at least one of the following criteria: * subject must demonstrate symptoms consistent with a suspected std such as vaginal odor, vaginal discharge, vaginal/vulvar itching or irritation, pain/discomfort during sexual intercourse or urination, and/or lower abdominal discomfort * subject must be asymptomatic and known to be partners with, or a contact of, a person with a confirmed or suspected std(s) * subject must be asymptomatic and undergoing screening evaluation for possible stds * subject must be undergoing pap screening exclusion criteria: * subject took antibiotic medications within the last 14 days * subject already participated in the study * subject has a history of illness that the principal investigator (pi) or designee considers could interfere with or affect the conduct, results, and/or completion of the clinical trial * subject has a history of illness that the pi or designee considers could create an unacceptable risk to the subject if enrolled

Keywords: aptima trichomonas vaginalis assay aptima trichomonas trichomonas vaginalis
afatinib in lung cancer with egfr mutation from circulating tumor dna

Conditions: Lung Neoplasms; EGFR Gene Mutation

Summary: treatment efficacy of afatinib will be assessed in patients with lung cancer harboring egfr mutations which were detected from circulating tumor dna.

obtaining tumor tissue or cytology samples are not always available in some patients with lung cancer. recently, studies showed that circulating tumor dna can be used as a suitable substitute for mutation analysis. the sensitivity of egfr mutation tests using circulating tumor dna was reported in the range of 65.7% (10) to 75% (11), with high specificity and positive predictive value. in this trial, treatment efficacy of afatinib will be assessed in patients with nsclc harboring egfr mutations which were detected from circulating tumor dna.

Eligibility criteria:
inclusion criteria: 1. stage iiib or iv lung cancer diagnosed radiologically with or without pathologic diagnosis 2. age\> 18 year-old 3. ecog performance status 0\~2. 4. activating egfr mutation (g719x, exon 19 deletion, l858r, l861q) detected from circulating dna 5. any one of the following criteria should be met * unavailable or failed pathologic/cytologic diagnosis * wild type or failed egfr testing based on tumor tissue * no more tumor sample available for egfr test 6. measurable lesion by recist v1.1 7. females should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test prior to start of dosing or evidence of non-child bearing potential. 8. male patients should be willing to use barrier contraception. 9. provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses 10. adequate organ function, defined as all of the following: * absolute neutrophil count (anc) \>=1500/mm3 * platelet count \>= 75,000 /mm3 * serum creatinine \< 1.4 mg/dl * ast or alt \< three times the upper limit of normal exclusion criteria: 1. prior exposure to egfr-tki. prior chemotherapy will be permitted. 2. previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured. 3. severe or unstable medical conditions such as history or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure nyha classification of ≥ 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. myocardial infarction within 6 months prior to randomisation. 4. known pre-existing interstitial lung disease 5. any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. crohn's disease, ulcerative colitis, chronic diarrhoea, malabsorption) 6. active hepatitis b infection (defined as presence of hepb sag and hep b dna), active hepatitis c infection (defined as presence of hep c rna) and/or known hiv carrier.
comparison of prosthetic femoropopliteal bypass versus viabahn endoprosthesis for treatment of symptomatic femoral artery occlusive disease

Conditions: Atherosclerosis; Lower Extremity Ischemia; Claudication; Rest Pain

Summary: this study is a comparison of two different ways to treat blockage in the artery of the thigh. the first is an older way with incisions in the groin and just above the knee. a plastic tube is then inserted to make a bypass from the groin to the knee. the second treatment offered is through a needle hole in the groin. a thin plastic tube covering a metal stent is inserted into the artery and released to bypass the blockage from inside the artery. no incisions are needed. patients are enrolled and then selected for one treatment method or another by chance. the patients will be followed for two years to see how the two different treatment methods work compared to each other.


Eligibility criteria:
inclusion criteria:patients that had atherosclerotic stenotic or occlusive lesions of the superficial femoral artery with no significant aorto-iliac disease. the infra-popliteal segment had to be patent with at least single vessel run-off to the ankle. patients had to be acceptable surgical candidates in the event they were randomized to the surgical arm. - exclusion criteria:non-operative candidate,contraindication to iv contrast use, planned surgery with venous conduit, previously stented segment of the superficial femoral artery, poorly compliant patient. -

Keywords: atherosclerosis stent angioplasty covered stent
biomarkers in giant cells arteritis

Conditions: Giant Cells Arteritis

Summary: giant cells arteritis or horton disease is a vasculitis that affects great vessels. this is the most frequent vasculitis of the population over the age of 50. this vasculitis is at the origin of an inflammatory infiltrate of arterial tunics, essentially composed of lymphocytes. clinical signs are a deterioration of general state, unusual cephalgias, jaw pain, scalp hyperesthesia, but can also be serious ischemic complication, especially ophthalmologic with the possibility to go blind. until now, the standard treatment is a high dosage corticosteroid therapy. diagnosis is based on criterias of the american college of rheumatology, dating back to 1990. the relapse rate is important, ranging from 10 to 64 % according to studies. there are also issues of becoming dependent on steroid. so it is important to determine new diagnosis markers and a therapeutic following of giant cells arteritis. with this study several biomarkers of inflammation will be studied in order to determine if one ore many of them have a good sensitivity and special feature for diagnosis and following of giant cells arteritis. the main goal is to determine a new diagnosis marker for giant cells arteritis.


Eligibility criteria:
inclusion criteria: * patient suffering from giant cells arteritis. * inclusion while discovery of symptoms, or during relapse. exclusion criteria: * healthy volunteer * treatment with corticosteroid since more than 8 days for a patient suffering from giant cells arteritis, exept for patients under corticosteroid for a polymyalgia rheumatica. * other diseases than giant cells arteritis that could introduce an inflammatory symptom, especially a tumoral process in progress or a chronic inflammatory disease (any other one than giant cells arteritis)

Keywords: arteritis biomarker horton disease